RESUMEN
BACKGROUND: Pericardiocentesis (PCC) with extended catheter drainage has become a relatively safe procedure to control pericardial effusion (PE), but little is known about long-term outcomes after PCC in malignant PE. OBJECTIVES: This study evaluated the effects of anti-inflammatory agents on long-term outcomes after effective drainage of PE in active cancer patients. METHODS: From May 2007 to December 2018, 445 patients with malignant PE who underwent echocardiography-guided PCC were enrolled. Clinical, laboratory, echocardiographic and procedural findings, and clinical outcome data were collected. Use of anti-inflammatory agents including colchicine, nonsteroidal anti-inflammatory drugs, or steroids after PCC was also analyzed. Colchicine was administered in a dose of 0.6 mg orally, twice a day for 2 months. The primary outcome was defined as a composite of all-cause death and re-PCC or pericardial window operation due to recurred PE. RESULTS: The procedure was successful in 97.0% of the cases, with 1 procedure-related death. During the follow-up of 2 years, 26.1% of patients developed recurrent PE, and 46.0% developed constrictive pericarditis. The colchicine treatment group showed a significantly lower risk of composite events (adjusted hazard ratio [aHR]: 0.65; 95% confidence interval [CI]: 0.49 to 0.87; p = 0.003) as well as all-cause death (aHR: 0.60; 95% CI: 0.45 to 0.81; p = 0.001) than did the noncolchicine group. On propensity score matching, colchicine after PCC was consistently associated with a lower composite events (aHR: 0.55; 95% CI: 0.37 to 0.82; p = 0.003). CONCLUSIONS: In cancer patients with malignant PE, PCC with extended drainage can be an appropriate therapeutic option and shows low complication rate. Patients receiving colchicine after successful PCC showed significant improvement in clinical outcome.
Asunto(s)
Colchicina/uso terapéutico , Neoplasias/complicaciones , Derrame Pericárdico/cirugía , Pericardiocentesis/efectos adversos , Pericarditis Constrictiva/prevención & control , Anciano , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Derrame Pericárdico/etiología , Pericarditis Constrictiva/epidemiología , Pericarditis Constrictiva/etiología , República de Corea/epidemiología , Estudios RetrospectivosRESUMEN
BACKGROUND: Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. CASE PRESENTATION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA) was used. Management of PP requires a combined surgical and medical approach. The most important is complete drainage of the effusion by subxiphoid pericardiotomy connected with complementary use of broad-spectrum antibiotics. Despite the use of broad- spectrum antibiotics, in some patients a large volume of daily drainage is still present. Constrictive pericarditis as a complication of PP is observed in majority of patients. Intrapericardial administration of fibrinolytic agents, although not strongly recommended, can improve efficacy of antibiotic treatment especially in patients with loculation fluid and can prevent the development of constrictive pericarditis. r-tPA was applied at a dose of 20 mg dissolved in 100 ml of normal saline in a 100 ml syringe, administered by a large pericardial drain (Pezzer drain) installed into the pericardial cavity during pericardioscopy. The tube was closed and re-opened after 24 h. No serious complications, such as bleeding, allergy or hypotension, were noted. CONCLUSION: We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA), prevented the development of constrictive pericarditis, and increased efficacy of antibiotic treatment without any significant complications.
Asunto(s)
Fibrinolíticos/administración & dosificación , Pericarditis Constrictiva/prevención & control , Pericarditis/tratamiento farmacológico , Activador de Tejido Plasminógeno/administración & dosificación , Adulto , Anciano , Antibacterianos/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pericardiectomía , Pericarditis/diagnóstico por imagen , Pericarditis/microbiología , Pericarditis Constrictiva/diagnóstico por imagen , Pericarditis Constrictiva/microbiología , Proteínas Recombinantes/administración & dosificación , Resultado del TratamientoRESUMEN
INTRODUCTION: Tuberculous (TB) pericarditis carries significant mortality and morbidity rates, not only during the primary infection, but also as part of the granulomatous scar-forming fibrocalcific constrictive pericarditis so commonly associated with this disease. Numerous therapies have previously been investigated as adjuvant strategies in the prevention of pericardial constriction. Colchicine is well described in the treatment of various aetiologies of pericarditis. The aim of this research was to investigate the merit for the use of colchicine in the management of tuberculous pericarditis, specifically to prevent constrictive pericarditis. METHODS: This pilot study was designed as a prospective, double-blinded, randomised, control cohort study and was conducted at a secondary level hospital in the Northern Cape of South Africa between August 2013 and December 2015. Patients with a probable or definite diagnosis of TB pericarditis were included (n = 33). Study participants with pericardial effusions amenable to pericardiocentesis underwent aspiration until dryness. All patients were treated with standard TB treatment and corticosteroids in accordance with the South African Tuberculosis Treatment Guidelines. Patients were randomised to an intervention and control group using a web-based computer system that ensured assignment concealment. The intervention group received colchicine 1.0 mg per day for six weeks and the control group received a placebo for the same period. Patients were followed up with serial echocardiography for 16 weeks. The primary outcome assessed was the development of pericardial constriction. Upon completion of the research period, the blinding was unveiled and data were presented for statistical analysis. RESULTS: TB pericarditis was found exclusively in HIV-positive individuals. The incidence of pericardial constriction in our cohort was 23.8%. No demonstrable benefit with the use of colchicine was found in terms of prevention of pericardial constriction (p = 0.88, relative risk 1.07, 95% CI: 0.46-2.46). Interestingly, pericardiocentesis appeared to decrease the incidence of pericardial constriction. CONCLUSION: Based on this research, the use of colchicine in TB pericarditis cannot be advised. Adjuvant therapy in the prevention of pericardial constriction is still being investigated and routine pericardiocentesis may prove to be beneficial in this regard.
Asunto(s)
Antiinflamatorios/uso terapéutico , Colchicina/uso terapéutico , Pericarditis Constrictiva/prevención & control , Pericarditis Tuberculosa/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Adulto , Antituberculosos/uso terapéutico , Coinfección , Método Doble Ciego , Ecocardiografía Doppler en Color , Ecocardiografía Doppler de Pulso , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Humanos , Incidencia , Masculino , Derrame Pericárdico/microbiología , Derrame Pericárdico/terapia , Pericardiocentesis , Pericarditis Constrictiva/diagnóstico por imagen , Pericarditis Constrictiva/epidemiología , Pericarditis Constrictiva/microbiología , Pericarditis Tuberculosa/diagnóstico por imagen , Pericarditis Tuberculosa/epidemiología , Pericarditis Tuberculosa/microbiología , Proyectos Piloto , Estudios Prospectivos , Factores de Riesgo , Sudáfrica/epidemiología , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis. METHODS: Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. RESULTS: There was no significant difference in the primary outcome between patients who received prednisolone and those who received placebo (23.8% and 24.5%, respectively; hazard ratio, 0.95; 95% confidence interval [CI], 0.77 to 1.18; P=0.66) or between those who received M. indicus pranii immunotherapy and those who received placebo (25.0% and 24.3%, respectively; hazard ratio, 1.03; 95% CI, 0.82 to 1.29; P=0.81). Prednisolone therapy, as compared with placebo, was associated with significant reductions in the incidence of constrictive pericarditis (4.4% vs. 7.8%; hazard ratio, 0.56; 95% CI, 0.36 to 0.87; P=0.009) and hospitalization (20.7% vs. 25.2%; hazard ratio, 0.79; 95% CI, 0.63 to 0.99; P=0.04). Both prednisolone and M. indicus pranii, each as compared with placebo, were associated with a significant increase in the incidence of cancer (1.8% vs. 0.6%; hazard ratio, 3.27; 95% CI, 1.07 to 10.03; P=0.03, and 1.8% vs. 0.5%; hazard ratio, 3.69; 95% CI, 1.03 to 13.24; P=0.03, respectively), owing mainly to an increase in HIV-associated cancer. CONCLUSIONS: In patients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant effect on the composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. (Funded by the Canadian Institutes of Health Research and others; IMPI ClinicalTrials.gov number, NCT00810849.).
Asunto(s)
Glucocorticoides/uso terapéutico , Inmunoterapia , Mycobacterium , Pericarditis Tuberculosa/tratamiento farmacológico , Prednisolona/uso terapéutico , Adulto , Taponamiento Cardíaco/etiología , Taponamiento Cardíaco/prevención & control , Terapia Combinada , Femenino , Glucocorticoides/efectos adversos , Infecciones por VIH/complicaciones , Humanos , Estimación de Kaplan-Meier , Masculino , Mycobacterium/inmunología , Pericardiocentesis , Pericarditis Constrictiva/etiología , Pericarditis Constrictiva/prevención & control , Pericarditis Tuberculosa/complicaciones , Pericarditis Tuberculosa/mortalidad , Prednisolona/efectos adversos , Insuficiencia del TratamientoRESUMEN
La pericarditis purulenta se define como la ocupación del saco pericárdico por fluido purulento. Es una enfermedad de curso letal si no se trata con prontitud; la mortalidad varía de 2 a 20 por ciento. La combinación de antibioticoterapia y drenaje pericárdico provee los mejores resultados clínicos, sin embargo, existe controversia en relación con el momento y la vía para realizarlo. Algunos enfermos desarrollan adherencias pericárdicas que producen constricción con repercusión hemodinámica por compromiso del llenado diastólico de las cavidades cardíacas derechas. Se presenta un paciente masculino, de 4 años de edad y 13 kg de peso corporal, con el diagnóstico de pericarditis purulenta de un mes de evolución, con signos de respuesta inflamatoria sistémica y compromiso hemodinámico por pericarditis constrictiva. Se intervino quirúrgicamente de urgencia para realizar pericardiectomía y drenaje del absceso mediastinal. Se comentan la prevención y la conducta ante esta grave complicación
Purulent pericarditis is defined as the occupation of the pericardial sac by the purulent effusion. It is a lethal disease if not treated as early as possible since the mortality rate ranges 2 to 20 percent. The combination of antibiotics and pericardial drainage provides the best clinical results; however, there are controversies about the time and the way of performing these actions. Some patients develop pericardial adhesions that may cause constriction with hemodynamic repercussion due to compromised dyastolic filling of the right heart cavities. Here is a male 4 years-old patient weighing 13 kg, who was diagnosed with purulent pericarditis of one month of evolution and presented signs of systemic inflammation and hemodynamic compromise due to constrictive pericarditis. He was operated on at the emergency service to perform pericardiectomy and mediastinal abscess drainage. The prevention of this problem and the behavior to be followed to manage this serious complication were commented on in this report
Asunto(s)
Humanos , Masculino , Preescolar , Drenaje/métodos , Pericarditis Constrictiva/cirugía , Pericarditis Constrictiva/prevención & control , Pericardiectomía/métodosRESUMEN
OBJECTIVES: This study aimed to describe our experience with pediatric bacterial pericarditis and review the optimal therapy for this entity. METHODS: This is a retrospective study in a pediatric intensive care unit in a university hospital. Three children were diagnosed with purulent pericarditis. They were all treated with antibiotics, echocardiography-guided pericardial fluid drainage, and placement of a pericardial catheter, with no need for thoracotomy or pericardial window. RESULTS: All 3 children fully recovered, and none developed constrictive pericarditis. CONCLUSIONS: Children with purulent pericarditis usually can be treated with antibiotics and drainage of pericardial effusion, with no need for thoracotomy or pericardial window.
Asunto(s)
Antibacterianos/uso terapéutico , Cateterismo/métodos , Drenaje/métodos , Pericardiectomía , Pericardiocentesis , Pericarditis/cirugía , Infecciones Estafilocócicas/complicaciones , Infecciones Estreptocócicas/complicaciones , Streptococcus pyogenes/aislamiento & purificación , Procedimientos Innecesarios , Taponamiento Cardíaco/diagnóstico por imagen , Taponamiento Cardíaco/etiología , Preescolar , Terapia Combinada , Urgencias Médicas , Femenino , Humanos , Lactante , Unidades de Cuidado Intensivo Pediátrico , Pericarditis/tratamiento farmacológico , Pericarditis Constrictiva/prevención & control , Infecciones Neumocócicas/complicaciones , Infecciones Neumocócicas/diagnóstico , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/cirugía , Estudios Retrospectivos , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/cirugía , Infecciones Estreptocócicas/diagnóstico , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/cirugía , Supuración , Ultrasonografía Intervencional , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Activador de Plasminógeno de Tipo Uroquinasa/uso terapéuticoRESUMEN
OBJECTIVE: To investigate whether intrapericardial urokinase irrigation along with pericardiocentesis could prevent pericardial constriction in patients with infectious exudative pericarditis. METHODS: A total of 94 patients diagnosed as infectious exudative pericarditis (34 patients with purulent pericarditis and 60 with tuberculous pericarditis, the disease courses of all patients were less than 1 month), 44 males and 50 females, aged from 9 to 66 years (mean 45.4 +/- 14.7 years), were consecutively recruited from 1993 to 2002. All individuals were randomly given either intrapericardial urokinase along with conventional treatment in study group, or conventional treatment alone (including pericardiocentesis and drainage) in control group. The dosage of urokinase ranged from 200000 to 600000 U (mean 320000 +/- 70000 U). The immediate effects were detected by pericardiography with sterilized air and diatrizoate meglumine as contrast media. The long-term investigation depended on the telephonic survey and echocardiographic examination. The duration of following-up ranged from 8 to 120 months (mean 56.8 +/- 29.0 months). RESULTS: Percutaneous intrapericardial urokinase irrigation promoted complete drainage of pericardial effusion, significantly reduced the thickness of pericardium (from 3.1 +/- 1.6 mm to 1.6 +/- 1.0 mm in study group, P < 0.001; from 3.4 +/- 1.6 mm to 3.2 +/- 1.8 mm in control group, P > 0.05, respectively), and alleviated the adhesion. Intrapericardial bleeding related to fibrinolysis was found in 6 of 47 patients with non-blood pericardial effusion and no systemic bleeding and severe puncture-related complication was observed. In follow-up, there was no cardiac death, and pericardial constriction events were observed in 9 (19.1%) of study group and 27 (57.4%) of control group. Cox analysis illustrated that urokinase could significantly reduce the occurrence of pericardial constriction (relative hazard coefficient = 0.185, P < 0.0001). CONCLUSION: The early employment of intrapericardial fibrinolysis with urokinase and pericardiocentesis appears to be safe and effective in preventing the development of pericardial constriction in patients with infectious exudative pericarditis.
Asunto(s)
Fibrinolíticos/administración & dosificación , Pericarditis Constrictiva/prevención & control , Pericarditis/tratamiento farmacológico , Terapia Trombolítica , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Adolescente , Adulto , Anciano , Niño , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pericardiocentesis , Pericarditis/terapiaAsunto(s)
Taponamiento Cardíaco/prevención & control , Derrame Pericárdico/prevención & control , Pericarditis Constrictiva/prevención & control , Pericarditis/complicaciones , Taponamiento Cardíaco/etiología , Humanos , Derrame Pericárdico/etiología , Pericarditis/etiología , Pericarditis Constrictiva/etiología , Factores de RiesgoRESUMEN
Patients of chronic exudative pericardial effusion are frequently treated with antitubercular treatment on presumptive grounds in developing countries, in a hope to prevent constrictive pericarditis. To assess the impact of antitubercular treatment on development of constrictive pericarditis in chronic large exudative pericarditis effusion of undetermined etiology, 25 patients above 12 years of age, with large pericarditis effusion beyond 12 weeks duration, were randomized in a prospective 2:1 fashion, to receive either 3-drug antitubercular treatment (group A) or placebo (group B) for six months. End points studied were, development of pericardial thickness as diagnosed by CT scan and constrictive pericarditis as diagnosed by cardiac catheterization. Twenty-one patients (14 in group A and 7 in group B) completed the study protocol. In all, five (23.8%) patients developed constrictive pericarditis/pericardial thickening. Histopathological examination of pericardiectomy specimens in over five patients were negative for tubercular pathology. Pericardial effusion resolved completely in another 10 (47.8%) patients. There was no significant difference in both the groups in development of constrictive pericarditis/pericardial thickening (group A: n = 3, 21.4% and group B: n = 2, 29.6%, p = NS). On multivariate analysis, development of constrictive pericarditis/pericardial thickening was associated with recurrent tamponade (p = 0.01), presence of tamponade at admission (p = 0.07) and haemorrhagic pericardial effusion (p = 0.08). Thus, antitubercular treatment does not prevent the development of constrictive pericarditis in patients of large chronic pericardial effusion of undetermined etiology.
Asunto(s)
Antituberculosos/uso terapéutico , Derrame Pericárdico/tratamiento farmacológico , Pericarditis Constrictiva/prevención & control , Adulto , Enfermedad Crónica , Quimioterapia Combinada , Ecocardiografía , Etambutol/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Isoniazida/administración & dosificación , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pericarditis Constrictiva/diagnóstico por imagen , Pericarditis Constrictiva/epidemiología , Estudios Prospectivos , Rifampin/administración & dosificación , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
Three male patients with purulent pericarditis, in whom complete drainage could not be obtained by pericardiocentesis, were treated with transcatheter intrapericardial urokinase to prevent the development of chronic constrictive pericarditis. As shown by echocardiography, the intrapericardial fibrin layers disappeared in two cases and were reduced by more than half in the third. Effects on systemic coagulation indices and complications related to intrapericardial lysis were not observed.
Asunto(s)
Pericarditis/tratamiento farmacológico , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Adulto , Drenaje , Ecocardiografía , Fibrinólisis , Humanos , Masculino , Persona de Mediana Edad , Pericarditis Constrictiva/prevención & controlRESUMEN
The incidence of Hemophilus influenzae, type B, infections in children has been increasing recently, so the number of cases of pericarditis is likely to rise also. We describe the clinical manifestations and treatment of H. influenzae, type B, pericarditis based on 4 patients and a review of the literature. The most common complication is cardiac tamponade, which requires drainage. All patients should be treated with antibiotics (chloramphenicol, ampicillin) and a drainage procedure. Because of several recently reported cases of subsequent constrictive pericarditis, we recomment anterior interphrenic pericardiectomy both for drainage and to prevent constrictive pericarditis. With appropriate therapy the survival rate should be very high.